Role of Biomarkers in the Study and Management of Inflammatory Bowel Disease

Sachar, David B.

doi:10.1097/mib.0000000000000135

Cited by 21 publications

(15 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, future studies need to implement psychological techniques to enhance motivation, self-regulation and self-reflection, in order to enable patients implement PA for their individual disease management [83]. An agreement in standardized assessment instruments including the most important health outcomes in IBD would be necessary for the quantitative synthesis of future studies [28, 84]. The interventions as well as outcome assessments should be multidimensional, i.e.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Structured physical activity interventions as a complementary therapy for patients with inflammatory bowel disease – a scoping review and practical implications

et al. 2019

View full text Add to dashboard Cite

Background Patients with Inflammatory Bowel Disease (IBD) also suffer from a wide range of additional disorders, which may be caused by the disease, the side effect of the medication, or a lack of physical activity (PA). This results in reduced physical and psychological wellbeing. However, as known from other chronic diseases exercise could be utilized as supportive therapy for IBD patients. Main goals of this article are (a) collecting data of the effects structured physical activity interventions have on validated clinical parameters of IBD and health related symptoms, (b) developing activity recommendations for this clientele. Methods A scoping review was conducted, searching for relevant articles published until May 2018, which investigated the effects of structured exercise interventions in IBD patients. The heterogeneity of the outcomes and the interventions did not support a quantitative synthesis thus, a qualitative discussion of the studies is provided. Results After reviewing 353 records, 13 eligible articles were identified. Five studies investigated aerobic exercise, three studies resistance exercise, three studies mind-body therapies and two studies yoga. The quality of the studies is mixed, and the duration is rather short for exercise interventions. Only few studies assessed validated IBD activity markers or inflammatory biomarkers. Nevertheless, the patients showed an increase in fitness, bone mineral density (BMD), quality of life and a decrease of IBD induced stress and anxiety. No severe adversial events were reported. Conclusion Even though the evidence is limited the application of exercise interventions in IBD patients can be assumed to be safe and beneficial for the patients‘ overall-health, and IBD specific physical and psychosocial symptoms. But there is still a high demand for more thoroughly conducted studies, focussing on important clinical outcome parameters.

show abstract

Section: Resultsmentioning

confidence: 99%

“…An agreement in standardized assessment instruments including the most important health outcomes in IBD would be necessary for the quantitative synthesis of future studies [28, 84]. The interventions as well as outcome assessments should be multidimensional, i.e.…”

Section: Resultsmentioning

confidence: 99%

Structured physical activity interventions as a complementary therapy for patients with inflammatory bowel disease – a scoping review and practical implications

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Stool-based markers may also assist in the determination of possible gut inflammation in individuals with undifferentiated symptoms [13,14] . Whilst identification of faecal white cells or measurement of faecal α-1-antitrypsin can be utilised, neither of these tests provides adequate sensitivity or specificity for gut inflammation [15] .…”

Section: Discussionmentioning

confidence: 99%

Inflammatory Markers in Children with Newly Diagnosed Inflammatory Bowel Disease

Day¹,

Hamilton

Leach

et al. 2017

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

AIM: Various markers of inflammation are commonly utilised in the assessment of children with symptoms suggestive of Inflammatory Bowel Disease (IBD). The aim of this study was to outline the results of standard inflammatory markers in a large group of children at the time of diagnosis with IBD. METHODS:The results of four standard inflammatory markers (ESR, albumin, platelet count and CRP) measured in a cohort of children diagnosed with IBD over a ten year period were reviewed retrospectively. Baseline demographic data, nutritional status (weight and height), disease type and disease location were also recorded. RESULTS: Data was available for 206 children diagnosed with IBD: 146 were diagnosed with Crohn disease (CD), 30 with ulcerative colitis (UC) and 30 with IBD unclassified (IBDU). Children with CD had longer duration of symptoms, and weighed less with lower BMI than children in the other disease groups. Furthermore, albumin levels were lower and platelets counts higher in children with CD. All four of the tests were normal in 13% of children with CD and 36% of those with IBDU. Children with CD were more likely to have abnormalities in all four tests. CONCLUSIONS: Children with CD were more likely to have abnormal systemic inflammatory markers and to have multiple

show abstract

“…In patients with Crohn's disease, the risk of relapse at 12 months decreased to 26% (15% to 37%; I 2 =0%; 57 patients) when the analysis was restricted to patients in whom clinical and endoscopic Today, there is a strong movement to substitute the index or other symptom based scores with objective biologic (C reactive protein (CRP) or calprotectin), radiologic, or endoscopic markers of active inflammation. [106][107][108][109][110][111] The aim of using such quantitative measures is to identify structural damage to the bowel, 112 confirm mucosal healing, [113][114][115] and select therapeutic targets. 116 Potential objective markers of inflammation that are abnormal at the onset of treatment should be identified and monitored over time to assess response.…”

Section: Stopping or Reducing The Dose Of Anti-tnf Drugsmentioning

confidence: 99%

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

Cohen

Sachar

2017

BMJ

115

View full text Add to dashboard Cite

The treatment of inflammatory bowel disease (IBD)-ulcerative colitis (UC) and Crohn's disease (CD)-has evolved beyond surgery with the introduction of biologic agents, primarily antibodies against mediators of inflammation and cell attraction. Anti-tumor necrosis factor (TNF) agents have been the first line treatment for moderate to severe ulcerative colitis and Crohn's disease for more than 15 years. During that time much has been learnt about how best to use these agents. This review will assess the evidence on how to optimize the use of anti-TNF agents; when and how to start treatment; how to monitor treatment and when to de-escalate it; and the potential adverse effects of these drugs. New and emerging treatments such as anti-attractants, anti-interleukins, and Janus kinase (JAK) inhibitors will also be discussed.

show abstract

Role of Biomarkers in the Study and Management of Inflammatory Bowel Disease

Cited by 21 publications

References 112 publications

Structured physical activity interventions as a complementary therapy for patients with inflammatory bowel disease – a scoping review and practical implications

Structured physical activity interventions as a complementary therapy for patients with inflammatory bowel disease – a scoping review and practical implications

Inflammatory Markers in Children with Newly Diagnosed Inflammatory Bowel Disease

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

Contact Info

Product

Resources

About